Detalles de la búsqueda
1.
Genetic defects of gamma-secretase genes in a multiple myeloma patient with high and dysregulated BCMA surface density: A case report.
Br J Haematol;
204(2): 571-575, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37957838
2.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials.
Haematologica;
109(1): 245-255, 2024 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37439329
3.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials.
Hematol Oncol;
42(4): e3290, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38818978
4.
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma.
Blood;
137(22): 3027-3036, 2021 06 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33739404
5.
Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis.
Haematologica;
108(3): 833-842, 2023 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36200419
6.
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
Hematol Oncol;
40(4): 704-715, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35608183
7.
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
Eur J Haematol;
108(1): 73-83, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34496096
8.
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients.
Eur J Haematol;
108(3): 178-189, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34716957
9.
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Lancet Oncol;
22(12): 1705-1720, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34774221
10.
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Lancet;
396(10262): 1563-1573, 2020 11 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-33189178
11.
Safety of outpatient stem cell mobilization with low- or intermediate-dose cyclophosphamide in newly diagnosed multiple myeloma patients.
Eur J Haematol;
107(5): 566-572, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34297879
12.
Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse.
Br J Haematol;
188(6): 907-917, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31898319
13.
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Lancet Oncol;
20(6): 781-794, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31097405
14.
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials.
Haematologica;
106(1): 291-294, 2021 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32107338
15.
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.
Blood;
122(16): 2799-806, 2013 Oct 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-23954889
16.
Effect of novel agents on the risk of early death of newly diagnosed symptomatic multiple myeloma patients: A single Centre retrospective analysis.
Am J Hematol;
94(1): E11-E13, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30328638
17.
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study.
Am J Hematol;
89(12): 1085-91, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25159313
18.
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment.
Clin Lymphoma Myeloma Leuk;
24(3): 165-176.e4, 2024 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38072743
19.
A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience.
Cancer Med;
13(7): e7071, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38558233
20.
Phase I study of the heparanase inhibitor roneparstat: an innovative approach for ultiple myeloma therapy.
Haematologica;
103(10): e469-e472, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29700168